Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
A study to explore the correlation of ABCB1, ABCG2, OCT1 genetic polymorphisms and trough level concentration with imatinib mesylate-induced thrombocytopenia in chronic myeloid leukemia patients
- J. Francis, B. Dubashi, R. Sundaram, S. Pradhan, A. Chandrasekaran
- Medicine
- Cancer Chemotherapy and Pharmacology
- 6 November 2015
PurposeImatinib mesylate is presently the first-line treatment for chronic myeloid leukemia (CML). Therapeutic drug monitoring (TDM) and pharmacogenetic screening is warranted for better management… Expand
Influence of Sokal, Hasford, EUTOS scores and pharmacogenetic factors on the complete cytogenetic response at 1 year in chronic myeloid leukemia patients treated with imatinib
- J. Francis, B. Dubashi, R. Sundaram, S. Pradhan, A. Chandrasekaran
- Medicine
- Medical Oncology
- 5 July 2015
Abstract
Imatinib mesylate is currently considered the first-line treatment for chronic myeloid leukemia (CML). Sokal, Hasford and EUTOS are the three major risk categorization scores available for… Expand
Functional outcome of tibial condyle fractures following open reduction and internal fixation with plate and screws
- J. Unnikrishnan, J. JacobP, J. Francis
- Medicine
- 4 August 2013
Aims and objectives To evaluate the functional outcome of tibial plateau fractures treated by open reduction and internal fixation with buttress plating. Materials and methods 25 patients with tibial… Expand
- 2
- 1
Correlation between MRI and arthroscopic findings in injuries of knee joint
- Manoj Mk, Brijesh Ray Rs, J. Francis
- Medicine
- 2014
injuries and its various types with arthroscopy, to find out the specificity, sensitivity, positive and negative predictive values of MRI in diagnosing different injuries, to know the role of… Expand
- 3
- 1
Antibiotic cement impregnated nailing in the management of infected non-union of femur and tibia
- R. Dhanasekhar, J. JacobP, J. Francis
- Medicine
- 4 August 2013
Infected non-union of long bones present a complex problem to the treating surgeon. The treatment of non-union follows traditionally followed a two staged procedure. More recently, single stage… Expand
- 10
A Population Pharmacokinetic Analysis Shows that Arylacetamide Deacetylase (AADAC) Gene Polymorphism and HIV Infection Affect the Exposure of Rifapentine
- J. Francis, S. Zvada, +13 authors H. McIlleron
- Medicine
- Antimicrobial Agents and Chemotherapy
- 22 January 2019
Rifapentine is a rifamycin used to treat tuberculosis. As is the case for rifampin, plasma exposures of rifapentine are associated with the treatment response. ABSTRACT Rifapentine is a rifamycin… Expand
Adverse drug reactions of imatinib in patients with chronic myeloid leukemia: A single-center surveillance study
- J. Francis, M. Palaniappan, B. Dubashi, S. Pradhan, A. Chandrasekaran
- Medicine
- Journal of pharmacology & pharmacotherapeutics
- 1 January 2015
Objective: To monitor the adverse drug reactions (ADRs) associated with imatinib treatment in patients with chronic myeloid leukemia (CML) in a tertiary care hospital. Materials and Methods: The… Expand
Arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of Rifapentine: a population pharmacokinetics analysis.
- J. Francis, Simbarashe P. Zvada, +13 authors H. McIlleron
- Biology
- 2019
Correlation of MRI with arthroscopy in injuries of knee joint
- Manoj Mk, Brijesh Ray Rs, J. Francis
- Medicine
- 5 March 2014
Aims and objectives Arthroscopy has remained the reference standard for the diagnosis of internal derangements of the knee, against which alternative diagnostic modalities should be compared. In this… Expand
- 3
A study to explore the correlation of trough level concentration and ABCB1, OCT1, ABCG2 genetic polymorphisms with imatinib mesylate induced thrombocytopenia in chronic myeloid leukemia patients.
- D. Biswajit, J. Francis, R. Sundaram, S. Pradhan, A. Chandrasekaran
- Medicine
- 20 May 2015
e13564 Background: Imatinib mesylate is presently the first line treatment for chronic myeloid leukemia (CML). Therapeutic drug monitoring (TDM) and pharmacogenetic screening is warranted for bette...